Eurofins Clinical Diagnostics laboratories offer genetic tests to evaluate predisposition towards heart disease for individuals with a family history of sudden cardiac death (including sudden infant death), heart failure or heart transplant.

Proper assessment of cardiovascular disease (CVD) risk requires non-standard lipid panels that consider HDL subpopulations. Eurofins HDL Map® takes into account the impact of different particle sizes, composition and characteristics of those subpopulations on CVD risk. We also offer assessment of cardiometabolic syndrome (CMS) risk, with a particular focus on prediabetes.

Both non-standard lipids panels and genetic tests are used to provide a diagnosis. Eurofins Clinical Diagnostics laboratories' innovative tests allow for earlier diagnosis of CVD risk and therefore better care and prognosis of patients with a cardiovascular disorder.

An understanding of metabolic pathways for production and absorption of cholesterol allows us to design the best cholesterol-lowering therapy based on statins, ezetimibe, PCSK9 inhibitors, probiotics, and bile acid sequestrants. Eurofins Clinical Diagnostics’ exclusive Statin Induced Myopathy (SLCO1B1) Genotype test is used to facilitate the selection of the most appropriate statin for treatment, and as a result minimises side effects and increases treatment adherence.

Eurofins Clinical Diagnostics laboratories offer testing for several markers that are related to disease progression and patient prognosis. Eurofins Clinical Diagnostics laboratories offer an array of innovative testing solutions to analyse aortic stenosis progression, to predict of hospital readmission and mortality,  and inflammation markers, such as High Sensitivity C-Reactive Protein (hs-CRP), to provide independent prognostic information.